CarboGen and AMCIS: Dedicated to Drug Development

Authors

  • Rolf Schaefer
  • Frank Kumli

DOI:

https://doi.org/10.2533/000942905777677019

Keywords:

Contract manufacturing, Contract research, Drug development, Oncology, Polymer-drug conjugates

Abstract

For 44 years of combined history, CarboGen and AMCIS have benefited from their prime location in Switzerland. The combined companies have flourished in a nation that delivers geographic, legislative, and economic benefits that are particularly appealing to developing pharmaceutical companies that serve global markets. Firmly committed to their combined mission of reducing the time, cost, and risks associated with drug development, CarboGen and AMCIS routinely apply innovative science and technology for industrial advantage. Together, these leading Swiss pharmaceutical industry suppliers serve to further science and advance therapeutic treatments that improve the human condition around the world.

Downloads

Published

2005-01-01

How to Cite